secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROCRINE BIOSCIENCES INC (NBIX)
CIK:        0000914475
Form:       8-K
Filed at:   2023-02-06T23:59:59+00:00
Accession:  0000914475-23-000005
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurocrine Q4 INGREZZA sales $399M; guides FY23 INGREZZA $1.67-1.77B
--------------------------------------------------------------------

- Q4 2022 INGREZZA net product sales $399M (+33% YoY); full year $1.43B.
- GAAP net income $89M ($0.88 diluted EPS) vs loss year-ago; non-GAAP net income $125M ($1.24 EPS).
- FY2023 INGREZZA sales guidance $1.67-1.77B (tardive dyskinesia only); GAAP R&D $550-580M, SG&A $850-870M.
- PDUFA date Aug 20, 2023 for valbenazine in Huntington chorea; crinecerfont registrational studies enrollment complete.
- Acquired Diurnal Group (~$55M) Nov 2022; entered Voyager partnership for GBA1 gene therapy Jan 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/914475/000091447523000005/0000914475-23-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/914475/000091447523000005/nbix-20230206.htm
  HTML page:      https://secwatch.observer/filing/0000914475-23-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer